Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses

Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses

Amid controversial reports that COVID-19 can be treated with a combination of the antimalarial drug hydroxychloroquine (HCQ) and the antibiotic azithromycin (AZI), a clinical trial (ONCOCOVID, NCT04341207) was launched at Gustave Roussy Cancer Campus to investigate the utility of this combination th...

Full description

Bibliographic Details
Main Authors: Peng Liu, Liwei Zhao, Gladys Ferrere, Carolina Alves-Costa-Silva, Pierre Ly, Qi Wu, Ai-Ling Tian, Lisa Derosa, Laurence Zitvogel, Oliver Kepp, Guido Kroemer
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
covid-19
sars-cov-2
immune checkpoint
hydroxychloroquine
immunotherapy
cancer
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1789284

Internet

http://dx.doi.org/10.1080/2162402X.2020.1789284

Similar Items